Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560

被引：14

作者：

Bateman, Kevin P. ^{[1
]}

Trimble, Laird ^{[1
]}

Chauret, Nathalie ^{[1
]}

Silva, Jose ^{[1
]}

Day, Stephen ^{[1
]}

Macdonald, Dwight ^{[1
]}

Dube, Daniel ^{[1
]}

Gallant, Michel ^{[1
]}

Mastracchio, Anthony ^{[1
]}

Perrier, Helene ^{[1
]}

Girard, Yves ^{[1
]}

Nicoll-Griffith, Deborah ^{[1
]}

机构：

[1] Merck Frosst Canada Inc, Pointe Claire, PQ H9R 4P8, Canada

来源：

JOURNAL OF MASS SPECTROMETRY | 2006年 / 41卷 / 06期

关键词：

phospodiesterase; metabolite identification; oxadiazole; L-454,560;

D O I：

10.1002/jms.1033

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

L-454,560 is a potent phospodiesterase 4 (PDE4) inhibitor which was identified as a development candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As part of the discovery of this compound, interspecies in vitro metabolism data was generated using liver microsomes and hepatocytes in order to understand the metabolic fate of the compound. In microsomes, metabolism of the 3-methyl-1,2,4-oxadiazole ring was the predominant pathway observed, including ring cleavage. In rat hepatocytes, hydroxylation of the methyl group on the oxadiazole ring and double-bond isomerization were the most abundant metabolites observed. No major species differences were found in terms of microsomal metabolite profiles. The use of LC with UV and MS detection is highlighted, as well as information from tandem mass spectrometry and NMR. Copyright (c) 2006 John Wiley & Sons, Ltd.

引用

页码：771 / 780

页数：10

共 20 条

[1] THE 5-LIPOXYGENASE INHIBITOR ZILEUTON BLOCKS ANTIGEN-INDUCED LATE AIRWAY RESPONSES, INFLAMMATION AND AIRWAY HYPERRESPONSIVENESS IN ALLERGIC SHEEP
ABRAHAM, WM
AHMED, A
CORTES, A
SIELCZAK, MW
HINZ, W
BOUSKA, J
LANNI, C
BELL, RL
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 217 (2-3) : 119 - 126
[2] The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-α and leukotriene B4 in a novel human whole blood assay
Brideau, C
Van Staden, C
Styhler, A
Rodger, IW
Chan, CC
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (04) : 979 - 988
[3] Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: Prevention of reactive intermediate formation and covalent binding
Chauret, N
Guay, D
Li, C
Day, S
Silva, J
Blouin, M
Ducharme, Y
Yergey, JA
Nicoll-Griffith, DA
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (16) : 2149 - 2152
[4] Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4-bis-difluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor
Claveau, D
Chen, SL
O'Keefe, S
Zaller, DM
Styhler, A
Liu, S
Huang, Z
Nicholson, DW
Mancini, JA
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (02) : 752 - 760
[5] Danahay H, 1998, CLIN EXP ALLERGY, V28, P513
[6] Day S. H., 2005, Journal of Pharmacological and Toxicological Methods, V52, P278, DOI 10.1016/j.vascn.2004.11.006
[7] Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development
Evans, DC
Watt, AP
Nicoll-Griffith, DA
Baillie, TA
[J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (01) : 3 - 16
[8] Proposed mechanisms for the fragmentation of doubly allylic alkenamides (tingle compounds) by low energy collisional activation in a triple quadrupole mass spectrometer
Hiserodt, RD
Pope, BM
Cossette, M
Dewis, ML
[J]. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2004, 15 (10) : 1462 - 1470
[9] Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3
[10] Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma
Jones, TR
McAuliffe, M
McFarlane, CS
Piechuta, H
Macdonald, D
Rodger, IW
[J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1998, 76 (02) : 210 - 217

← 1 2 →